Tag: Psychedelic Medicine

Definium Therapeutics has reported positive Phase III results for its LSD-based medicine DT120 in generalised anxiety disorder, giving the company ...

As psychedelic-assisted therapy moves from research into clinical practice in Australia, the organisations building the infrastructure around the sector are ...

The next phase of psychedelic drug development may not involve psychedelics in the traditional sense. As researchers and pharmaceutical companies ...

Australian psychedelic biotechnology company Entropy Neurodynamics (ASX: ENP) has secured Human Research Ethics Committee (HREC) approval to begin what it ...

Institutional investors are returning to psychedelic medicine in force, with the sector raising more than US$1 billion in a single ...

Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early ...

In 1962, an American chemist quietly created an experimental compound in a laboratory at Parke, Davis & Company. It was ...

LSD has moved a significant step closer to becoming an approved prescription medicine after Definium Therapeutics reported positive topline results ...

When Eli Lilly agreed to acquire Atai Beckley in a deal worth up to US$3.8 billion, it wasn't simply the ...

Medicinal cannabis and psychedelic medicine are often discussed as part of the same healthcare revolution. Both involve substances that spent ...